Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor

BACKGROUND: EGFR tyrosine kinase inhibitors (TKIs) have been developed for the treatment of EGFR mutated NSCLC. Parthenolide, a natural product of parthenolide, which belongs to the sesquiterpene lactone family and has a variety of biological and therapeutic activities, including anti-cancer effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoling, Huang, Riming, Li, Mingyue, Zhu, Zheng, Chen, Zhiyan, Cui, Liao, Luo, Hui, Luo, Lianxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686780/
https://www.ncbi.nlm.nih.gov/pubmed/33292235
http://dx.doi.org/10.1186/s12935-020-01658-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686780/
https://www.ncbi.nlm.nih.gov/pubmed/33292235
http://dx.doi.org/10.1186/s12935-020-01658-1

Ejemplares similares